E
KPTI icon

Ergoteles’s Karyopharm Therapeutics KPTI Stock Holding History

Ergoteles’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-15,827
Closed -$425K – 479
2023
Q2 		$425K Buy
+15,827
New +$682K 0.02% 679
2023
Q1 		– Sell
-888
Closed -$45.3K – 1513
2022
Q4 		$45.3K Buy
+888
New +$61.6K ﹤0.01% 1304

Other funds holding KPTI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Ergoteles's KPTI Position: Q3 2023 in Review

Ergoteles sold out of Karyopharm Therapeutics (KPTI) in Q3 2023, closing a stake of 15,827 shares — an estimated $425K sold.

Ergoteles first reported a position in KPTI in Q4 2022 and held it in 2 quarters. The position peaked at $425K in Q2 2023. 118 funds tracked by Wall St. Rank hold KPTI as of Q3 2023.

  • Ergoteles reported no remaining Karyopharm Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Ergoteles sold 15,827 Karyopharm Therapeutics shares in Q3 2023, an estimated $425K.
  • Ergoteles first reported a position in Karyopharm Therapeutics in Q4 2022 and held it in 2 quarters.
  • Ergoteles's Karyopharm Therapeutics position peaked at $425K in Q2 2023.
  • 118 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2023.

Based on Ergoteles's 13F filing for Q3 2023, filed 14 Nov 2023.